InBody Co.,Ltd (041830.KQ)
KRW 23400.0
(0.43%)
KRW 23400.0
(0.43%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 128.11 Billion KRW | 9.38% |
| 2022 | 117.12 Billion KRW | 19.66% |
| 2021 | 97.88 Billion KRW | 32.49% |
| 2020 | 73.88 Billion KRW | -11.11% |
| 2019 | 83.11 Billion KRW | 15.79% |
| 2018 | 71.78 Billion KRW | 4.93% |
| 2017 | 68.4 Billion KRW | 20.42% |
| 2016 | 56.8 Billion KRW | 17.01% |
| 2015 | 48.54 Billion KRW | 42.09% |
| 2014 | 34.16 Billion KRW | 32.05% |
| 2013 | 25.87 Billion KRW | 9.61% |
| 2012 | 23.6 Billion KRW | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 35.48 Billion KRW | 11.84% |
| 2024 Q2 | 37.7 Billion KRW | 9.74% |
| 2023 Q2 | 30.35 Billion KRW | -3.98% |
| 2023 Q1 | 31.61 Billion KRW | -5.98% |
| 2023 FY | 128.11 Billion KRW | 9.38% |
| 2023 Q3 | 34.41 Billion KRW | 13.38% |
| 2023 Q4 | 31.72 Billion KRW | -7.82% |
| 2022 Q3 | 26.97 Billion KRW | -4.32% |
| 2022 Q1 | 28.34 Billion KRW | 5.29% |
| 2022 FY | 117.12 Billion KRW | 19.66% |
| 2022 Q4 | 33.62 Billion KRW | 24.67% |
| 2022 Q2 | 28.18 Billion KRW | -0.55% |
| 2021 Q4 | 26.92 Billion KRW | 15.2% |
| 2021 Q1 | 23.71 Billion KRW | 8.01% |
| 2021 FY | 97.88 Billion KRW | 32.49% |
| 2021 Q2 | 23.88 Billion KRW | 0.74% |
| 2021 Q3 | 23.36 Billion KRW | -2.17% |
| 2020 Q1 | 20.35 Billion KRW | -9.17% |
| 2020 Q3 | 21.53 Billion KRW | 63.03% |
| 2020 Q4 | 21.95 Billion KRW | 1.91% |
| 2020 FY | 73.88 Billion KRW | -11.11% |
| 2020 Q2 | 13.21 Billion KRW | -35.09% |
| 2019 Q4 | 22.41 Billion KRW | 2.87% |
| 2019 Q3 | 21.78 Billion KRW | -2.04% |
| 2019 FY | 83.11 Billion KRW | 15.79% |
| 2019 Q1 | 19.26 Billion KRW | 4.68% |
| 2019 Q2 | 22.23 Billion KRW | 15.41% |
| 2018 Q1 | 15.86 Billion KRW | -18.83% |
| 2018 Q3 | 19.19 Billion KRW | 2.62% |
| 2018 Q2 | 18.7 Billion KRW | 17.91% |
| 2018 FY | 71.78 Billion KRW | 4.93% |
| 2018 Q4 | 18.4 Billion KRW | -4.12% |
| 2017 FY | 68.4 Billion KRW | 20.42% |
| 2017 Q4 | 19.54 Billion KRW | 9.96% |
| 2017 Q2 | 16.75 Billion KRW | 13.54% |
| 2017 Q1 | 14.75 Billion KRW | 3.98% |
| 2017 Q3 | 17.77 Billion KRW | 6.09% |
| 2016 Q4 | 14.19 Billion KRW | 6.83% |
| 2016 FY | 56.8 Billion KRW | 17.01% |
| 2016 Q3 | 13.28 Billion KRW | -4.44% |
| 2016 Q2 | 13.9 Billion KRW | -13.07% |
| 2016 Q1 | 15.99 Billion KRW | 15.1% |
| 2015 Q4 | 13.89 Billion KRW | 7.88% |
| 2015 FY | 48.54 Billion KRW | 42.09% |
| 2015 Q1 | 11.44 Billion KRW | 44.64% |
| 2015 Q2 | 10.82 Billion KRW | -5.42% |
| 2015 Q3 | 12.87 Billion KRW | 18.94% |
| 2014 Q1 | 8.92 Billion KRW | 47.71% |
| 2014 Q2 | 9.11 Billion KRW | 2.17% |
| 2014 Q3 | 8.21 Billion KRW | -9.92% |
| 2014 Q4 | 7.91 Billion KRW | -3.61% |
| 2014 FY | 34.16 Billion KRW | 32.05% |
| 2013 Q1 | 7.11 Billion KRW | 29.96% |
| 2013 Q4 | 6.04 Billion KRW | -6.24% |
| 2013 FY | 25.87 Billion KRW | 9.61% |
| 2013 Q2 | 6.27 Billion KRW | -11.77% |
| 2013 Q3 | 6.44 Billion KRW | 2.64% |
| 2012 Q3 | 5.79 Billion KRW | 0.0% |
| 2012 Q4 | 5.47 Billion KRW | -5.6% |
| 2012 FY | 23.6 Billion KRW | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Osang Healthcare Co.,Ltd | 219.75 Billion KRW | 41.703% |
| Curexo Inc. | 17.95 Billion KRW | -613.477% |
| Seegene, Inc. | 180.07 Billion KRW | 28.854% |
| i-SENS, Inc. | 101.04 Billion KRW | -26.794% |
| Ray Co., Ltd. | 65.08 Billion KRW | -96.831% |
| Gencurix Inc. | 422.03 Million KRW | -30256.378% |
| Sugentech Inc. | -5.88 Billion KRW | 2278.489% |
| L&C Bio Co., Ltd | 32.52 Billion KRW | -293.865% |